Revenues for Bausch Health (excl. B+L) was $1.01 billion, down 2%.
Bausch + Lomb segment reported revenues were $931 million, +5%.
Salix segment revenues were $496 million for Q1, compared with $464 million a year ago. Xifaxan, Relistor, and Trulance drove sales growth.
The company reported an EPS loss of $(0.55), compared with $(0.19) a year ago. Adjusted net income attributable to Bausch Health was $191 million, compared with $263 million a year ago, primarily due to higher operating expenses and foreign exchange headwinds.
Adjusted EPS came in at $0.52, missing the consensus of $0.72.
Adjusted EBITDA fell to $588 million from $732 million.
Guidance: The company confirmed its FY23 guidance for Bausch Health (excl. B+L) and is providing full-year consolidated sales guidance of $8.35 – $8.55 billion, compared to the consensus of $8.35 billion.
It forecasts FY23 adjusted EBITDA of $3.00 – $3.15 billion.
Price Action: BHC shares are down 18.6% at $6.02 on the last check Thursday.
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.